Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Ondansetron is a 5-HT3 receptor antagonist with antiemetic activity.
It is used in the control and prevention of nausea and vomiting.
Administered intravenously, intramuscularly, orally or rectally in one or two doses per day.
Since the last update, we have not found published data on its excretion in breastmilk.
Its high volume of distribution and short half-life make it unlikely that it will be excreted in milk in significant quantities.
It is considered by experts to be safe and of choice in breastfeeding (Reece-Stremtan 2017, Rowe 2016) and probably compatible by prestigious medical associations (Mahadevan 2006).
Its use is safe in children between 1 and 24 months (Khalil 2005).
Furthermore, use after a cesarean does not affect a positive start to breastfeeing (Uerpairojkit 2016) or the health of the baby (Nallam 2017, Elkomy 2015), or the production of prolactin (Hale 2017 p729, Lissoni 1994).